Parallel Advisors’s Avalo Therapeutics AVTX Stock Holding History

Parallel Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18	Hold	1	–	–	﹤0.01%	3912
2026 Q1	$15	Hold	1	–	–	﹤0.01%	3820
2025 Q4	$18	Hold	1	–	–	﹤0.01%	3599
2025 Q3	$13	Hold	1	–	–	﹤0.01%	3533
2025 Q2	$5	Hold	1	–	–	﹤0.01%	3527
2025 Q1	$8	Hold	1	–	–	﹤0.01%	3494
2024 Q4	$7	Hold	1	–	–	﹤0.01%	3508
2024 Q3	$10	Hold	1	–	–	﹤0.01%	3380
2024 Q2	$12	Hold	1	–	–	﹤0.01%	3295
2024 Q1	$22	Buy	+1	New	+$5	﹤0.01%	3256
2023 Q4	–	Hold	0	–	–	–	3331
2023 Q3	–	Hold	0	–	–	–	3374
2023 Q2	–	Hold	0	–	–	–	3367
2023 Q1	–	Hold	0	–	–	–	3417
2022 Q4	–	Hold	0	–	–	–	3333
2022 Q3	–	Hold	0	–	–	–	3136
2022 Q2	–	Hold	0	–	–	–	2991
2022 Q1	–	Hold	0	–	–	–	2964
2021 Q4	–	Hold	0	–	–	–	3077
2021 Q3	–	Hold	0	–	–	–	3070
2021 Q2	–	Hold	0	–	–	–	2927
2021 Q1	–	Hold	0	–	–	–	2786
2020 Q4	–	Hold	0	–	–	–	2563
2020 Q3	–	Hold	0	–	–	–	2555
2020 Q2	–	Hold	0	–	–	–	2443
2020 Q1	–	Hold	0	–	–	–	2387

Other funds holding AVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallel Advisors's AVTX Position: Q2 2026 in Review

Parallel Advisors held its Avalo Therapeutics (AVTX) position steady in Q2 2026 at 1 share worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

Parallel Advisors first reported a position in AVTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $22 in Q1 2024. 27 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Parallel Advisors held 1 share of Avalo Therapeutics worth $18 as of Q2 2026.
Parallel Advisors left its Avalo Therapeutics share count unchanged in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3912 holding.
Parallel Advisors first reported a position in Avalo Therapeutics in Q1 2024 and has held it in 10 quarters since.
Parallel Advisors's Avalo Therapeutics position peaked at $22 in Q1 2024.
27 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.